Transgene announces detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers
By @CcR34Tg|2020-10-26T18:53:22+01:00October 27th, 2020|Press release, TG4001, TG4001|Comments Off on Transgene announces detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers
About the Author: @CcR34Tg
Related Posts
- First Head & Neck Cancer Patient Treated in France in a Phase I trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
First Head & Neck Cancer Patient Treated in France in a Phase I trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy